Deutsche Cuts Merck Target To $59 On Competition From AbbVie, GSK
November 24, 2017 at 08:36 AM EST
Deutsche Bank analyst Gregg Gilbert lowered his price target for Merck (MRK) to $59 from $62 citing expectations for more competitive pressure on Zepatier and Zostavax.